PTRH2
Peptidyl-tRNA hydrolase 2, mitochondrial
Also known as: BIT1, CFAP37, CGI-147, PTH2, PTH2_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9Y3E5
- Gene
- PTRH2
- Ensembl
- ENSG00000141378
- Chromosome
- 17
- Canonical length
- 179 aa
- Protein class
- Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Potential drug targets, Predicted membrane proteins
- Subcellular location
- Mitochondria
OverviewNCBI Gene
The protein encoded by this gene is a mitochondrial protein with two putative domains, an N-terminal mitochondrial localization sequence, and a UPF0099 domain. In vitro assays suggest that this protein possesses peptidyl-tRNA hydrolase activity, to release the peptidyl moiety from tRNA, thereby preventing the accumulation of dissociated peptidyl-tRNA that could reduce the efficiency of translation. This protein also plays a role regulating cell survival and death. It promotes survival as part of an integrin-signaling pathway for cells attached to the extracellular matrix (ECM), but also promotes apoptosis in cells that have lost their attachment to the ECM, a process called anoikos. After loss of cell attachment to the ECM, this protein is phosphorylated, is released from the mitochondria into the cytosol, and promotes caspase-independent apoptosis through interactions with transcriptional regulators. This gene has been implicated in the development and progression of tumors, and mutations in this gene have been associated with an infantile multisystem neurologic, endocrine, and pancreatic disease (INMEPD) characterized by intellectual disability, postnatal microcephaly, progressive cerebellar atrophy, hearing impairment, polyneuropathy, failure to thrive, and organ fibrosis with exocrine pancreas insufficiency (PMID: 25574476). Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Mar 2015]
Canonical amino-acid sequenceUniProt
179 residues, UniProt reviewed canonical sequence.
>Q9Y3E5|PTRH2
1 MPSKSLVMEY LAHPSTLGLA VGVACGMCLG WSLRVCFGML PKSKTSKTHT DTESEASILG
61 DSGEYKMILV VRNDLKMGKG KVAAQCSHAA VSAYKQIQRR NPEMLKQWEY CGQPKVVVKA
121 PDEETLIALL AHAKMLGLTV SLIQDAGRTQ IAPGSQTVLG IGPGPADLID KVTGHLKLYLocalizationUniProt · AlphaFold · HPA
Whether an antibody against PTRH2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Other membrane
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.39
- Highest tissue expression
- 46 nTPM
Expression across tissuesHPA
Tissue
- epididymis: 46 nTPM
- liver: 43 nTPM
- urinary bladder: 41 nTPM
- adrenal gland: 32 nTPM
- skeletal muscle: 31 nTPM
- breast: 26 nTPM
Single-cell type
- epicardial cells: 230 nCPM
- cardiomyocytes: 203 nCPM
- myonuclei: 103 nCPM
- adipocytes: 78 nCPM
- myosatellite cells: 69 nCPM
- fibro-adipogenic progenitors: 68 nCPM
Immune cell
- non-classical monocyte: 87 nTPM
- classical monocyte: 69 nTPM
- intermediate monocyte: 68 nTPM
- plasmacytoid DC: 60 nTPM
- myeloid DC: 50 nTPM
- memory B-cell: 43 nTPM
Brain region
- white matter: 21 nTPM
- cerebral cortex: 20 nTPM
- pons: 20 nTPM
- midbrain: 19 nTPM
- hypothalamus: 18 nTPM
- medulla oblongata: 18 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about PTRH2.
Disease | AllUniProt
Conditions PTRH2 is implicated in, by any mechanism.
- Neurologic, endocrine, and pancreatic disease, multisystem, infantile-onset 1 (IMNEPD1) MIM:616263
Disease | GeneticClinVar
8 pathogenic / likely-pathogenic of 51 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Neurologic, endocrine, and pancreatic disease, multisystem, infantile-onset 1
- Neurologic, endocrine, and pancreatic disease, multisystem, infantile-onset
- Cerebellar ataxia
- Hearing impairment
- Global developmental delay
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.7
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.43
- DepMap mean gene effect
- -0.19
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 8% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- apoptotic process
- negative regulation of anoikis
- negative regulation of gene expression
- positive regulation of anoikis
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of PTRH2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads PTRH2 as an antibody target. Whether an autoantibody or antibody against PTRH2 could matter depends on whether native PTRH2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
PTRH2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label PTRH2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...